John A Roque, Iii

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3277411/publications.pdf

Version: 2024-02-01

643344 843174 1,445 21 15 20 citations h-index g-index papers 23 23 23 1949 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Fineâ€Feature Modifications to Strained Ruthenium Complexes Radically Alter Their Hypoxic Anticancer Activity ^{â€} . Photochemistry and Photobiology, 2022, 98, 73-84.	1.3	20
2	Interaction with a Biomolecule Facilitates the Formation of the Function-Determining Long-Lived Triplet State in a Ruthenium Complex for Photodynamic Therapy. Journal of Physical Chemistry A, 2022, 126, 1336-1344.	1,1	6
3	Anticancer Agent with Inexplicable Potency in Extreme Hypoxia: Characterizing a Light-Triggered Ruthenium Ubertoxin. Journal of the American Chemical Society, 2022, 144, 9543-9547.	6.6	48
4	Photodynamic therapy of melanoma with new, structurally similar, NIR-absorbing ruthenium (II) complexes promotes tumor growth control via distinct hallmarks of immunogenic cell death American Journal of Cancer Research, 2022, 12, 210-228.	1.4	0
5	Intraligand Excited States Turn a Ruthenium Oligothiophene Complex into a Light-Triggered Ubertoxin with Anticancer Effects in Extreme Hypoxia. Journal of the American Chemical Society, 2022, 144, 8317-8336.	6.6	32
6	It Takes Three to Tango: The Length of the Oligothiophene Chain Determines the Nature of the Longâ€Lived Excited State and the Resulting Photocytotoxicity of a Ruthenium(II) Photodrug. ChemPhotoChem, 2021, 5, 421-425.	1.5	12
7	Ruthenium Photosensitizers for NIR PDT Require Lowest-Lying Triplet Intraligand (3IL) Excited States. Journal of Photochemistry and Photobiology, 2021, 8, 100067.	1.1	8
8	Discovery of immunogenic cell death-inducing ruthenium-based photosensitizers for anticancer photodynamic therapy. Oncolmmunology, 2021, 10, 1863626.	2.1	22
9	Strained, Photoejecting Ru(II) Complexes that are Cytotoxic Under Hypoxic Conditions. Photochemistry and Photobiology, 2020, 96, 327-339.	1.3	38
10	Bis[pyrrolyl Ru(<scp>ii</scp>)] triads: a new class of photosensitizers for metal–organic photodynamic therapy. Chemical Science, 2020, 11, 12047-12069.	3.7	23
11	Intracellular Photophysics of an Osmium Complex bearing an Oligothiophene Extended Ligand. Chemistry - A European Journal, 2020, 26, 14844-14851.	1.7	10
12	TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro. Pharmaceuticals, 2020, 13, 137.	1.7	23
13	NIRâ€Absorbing Ru II Complexes Containing αâ€Oligothiophenes for Applications in Photodynamic Therapy. ChemBioChem, 2020, 21, 3594-3607.	1.3	9
14	Breaking the barrier: an osmium photosensitizer with unprecedented hypoxic phototoxicity for real world photodynamic therapy. Chemical Science, 2020, 11, 9784-9806.	3.7	67
15	Os(II) Oligothienyl Complexes as a Hypoxia-Active Photosensitizer Class for Photodynamic Therapy. Inorganic Chemistry, 2020, 59, 16341-16360.	1.9	37
16	Near-infrared absorbing Ru(<scp>ii</scp>) complexes act as immunoprotective photodynamic therapy (PDT) agents against aggressive melanoma. Chemical Science, 2020, 11, 11740-11762.	3.7	67
17	Photophysical Properties and Photobiological Activities of Ruthenium(II) Complexes Bearing π-Expansive Cyclometalating Ligands with Thienyl Groups. Inorganic Chemistry, 2019, 58, 10778-10790.	1.9	34
18	New Class of Homoleptic and Heteroleptic Bis(terpyridine) Iridium(III) Complexes with Strong Photodynamic Therapy Effects. ACS Applied Bio Materials, 2019, 2, 2964-2977.	2.3	45

#	Article	IF	CITATIONS
19	Predictive Strength of Photophysical Measurements for in Vitro Photobiological Activity in a Series of Ru(II) Polypyridyl Complexes Derived from π-Extended Ligands. Inorganic Chemistry, 2019, 58, 3156-3166.	1.9	29
20	Synthesis, Characterization and Photobiological Studies of Ru(<scp>II</scp>) Dyads Derived from <i>α</i> â€Oligothiophene Derivatives of 1,10â€Phenanthroline. Photochemistry and Photobiology, 2019, 95, 267-279.	1.3	16
21	Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433. Chemical Reviews, 2019, 119, 797-828.	23.0	899